Baroni L, Goggi S, Battaglino R et al
About SELECT clinical study SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for the prevention of major adverse cardiac events (MACE) in people with overweight or obesity and established cardiovascular disease with no prior history of diabetes
While short-term imaging rarely shows dramatic bone density change, longer-term studies may reveal subtle shifts
Medical review & safety notice For many conditions, followup matters
And then I said, enough point went back up and my enough point
Comparing the anchor chemistry across these molecules is one of the clearer ways to see how small lipid and linker changes translate into large pharmacokinetic differences